PTG Stock Overview
Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells.
Price History & Performance
|Historical stock prices|
|Current Share Price||zł43.60|
|52 Week High||zł73.90|
|52 Week Low||zł40.00|
|1 Month Change||-9.92%|
|3 Month Change||-26.10%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-29.67%|
Recent News & Updates
Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
|PTG||PL Biotechs||PL Market|
Return vs Industry: Insufficient data to determine how PTG performed against the Polish Biotechs industry.
Return vs Market: Insufficient data to determine how PTG performed against the Polish Market.
|PTG Average Weekly Movement||5.9%|
|Biotechs Industry Average Movement||8.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in PL Market||14.8%|
|10% least volatile stocks in PL Market||5.1%|
Stable Share Price: PTG is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PTG's weekly volatility (6%) has been stable over the past year.
About the Company
Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.
Poltreg Fundamentals Summary
|PTG fundamental statistics|
Is PTG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PTG income statement (TTM)|
|Cost of Revenue||zł282.00k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
May 27, 2022
|Earnings per share (EPS)||-0.80|
|Net Profit Margin||-340.13%|
How did PTG perform over the long term?See historical performance and comparison
Is Poltreg undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PTG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PTG's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: PTG is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.
PE vs Market: PTG is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PTG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PTG is good value based on its PB Ratio (2x) compared to the PL Biotechs industry average (4.5x).
How is Poltreg forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PTG's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if PTG's earnings are forecast to grow faster than the Polish market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PTG's revenue (80.8% per year) is forecast to grow faster than the Polish market (6% per year).
High Growth Revenue: PTG's revenue (80.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PTG's Return on Equity is forecast to be high in 3 years time
How has Poltreg performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PTG is currently unprofitable.
Growing Profit Margin: PTG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PTG's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: PTG has a negative Return on Equity (-3.63%), as it is currently unprofitable.
How is Poltreg's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PTG's short term assets (PLN106.0M) exceed its short term liabilities (PLN5.7M).
Long Term Liabilities: PTG's short term assets (PLN106.0M) exceed its long term liabilities (PLN436.0K).
Debt to Equity History and Analysis
Debt Level: PTG has more cash than its total debt.
Reducing Debt: Insufficient data to determine if PTG's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PTG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 45.8% each year
What is Poltreg current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PTG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Poltreg has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: PTG only recently listed within the past 12 months.
Poltreg S.A.'s employee growth, exchange listings and data sources
- Name: Poltreg S.A.
- Ticker: PTG
- Exchange: WSE
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł203.326m
- Shares outstanding: 4.66m
- Website: https://poltreg.tech
Number of Employees
- Poltreg S.A.
- Waly Piastowskie 1 lok. 1508
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.